ABBV241108C162500
- 0.00
- 0.000.00%
AbbVie Newsroom
AbbVie's (ABBV.US) CD3, CD20 dual-acting antibody acalabrutinib monoclonal antibody has applied for listing in China.
On November 6, the CDE website shows that AbbVie (ABBV.US)'s CD3/CD20 bispecific antibody epcoritamab, with the trade name Epkinly in the USA, has applied for listing in China.
Tuesday Market Closed Up, with Presidency in Sight | Wall Street Today
We Want YOU to Submit Questions for Election Night
Market Climbs for Election Day Excitement | Live Stock
AI Robot Trader Dumped Microsoft, Amazon Stocks and Went Defensive. Here's What It Bought.
Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?
Deutsche Bank Adjusts AbbVie Price Target to $180 From $175, Maintains Hold Rating
PureTech: White Most Recently Served as CFO at ImmunoGen Prior to AbbVie Acquisition >PRTC
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
Seaport Therapeutics Names Lauren White as Chief Financial Officer
Should We Be Delighted With AbbVie Inc.'s (NYSE:ABBV) ROE Of 75%?
Monday Market Moves Sideways, Election and FOMC in Sight | Wall Street Today
AbbVie | 10-Q: Q3 2024 Earnings Report
8 High-momentum Stocks Set for Success – Oppenheimer
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
Monday Market Mixed Before Crazy, Pivotal Week | Live Stock
AbbVie Analyst Ratings
Argus Research Upgrades AbbVie(ABBV.US) to Buy Rating
AbbVie Upgraded to Buy From Hold at Argus
M&A Deals Roundup: AbbVie, Blackstone, Take-Two Interactive and More